Penn Davis Mcfarland Inc. Buys 170,456 Shares of Roivant Sciences Ltd. $ROIV

Penn Davis Mcfarland Inc. boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,862,088 shares of the company’s stock after buying an additional 170,456 shares during the period. Roivant Sciences accounts for approximately 2.9% of Penn Davis Mcfarland Inc.’s portfolio, making the stock its 12th largest position. Penn Davis Mcfarland Inc. owned 0.27% of Roivant Sciences worth $28,173,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Perceptive Advisors LLC bought a new position in shares of Roivant Sciences in the 2nd quarter worth approximately $37,546,000. Orbimed Advisors LLC purchased a new stake in Roivant Sciences in the second quarter worth $31,324,000. Rubric Capital Management LP raised its holdings in Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after purchasing an additional 2,603,260 shares in the last quarter. Squarepoint Ops LLC lifted its position in Roivant Sciences by 2,580.0% during the second quarter. Squarepoint Ops LLC now owns 2,211,675 shares of the company’s stock valued at $24,926,000 after buying an additional 2,129,150 shares during the period. Finally, Candriam S.C.A. lifted its position in Roivant Sciences by 5,399.5% during the second quarter. Candriam S.C.A. now owns 1,503,994 shares of the company’s stock valued at $16,951,000 after buying an additional 1,476,646 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity

In related news, major shareholder Vivek Ramaswamy sold 353,745 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.05, for a total transaction of $7,800,077.25. Following the completion of the sale, the insider owned 34,132,463 shares of the company’s stock, valued at $752,620,809.15. This trade represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Richard Pulik sold 406,731 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the completion of the transaction, the chief financial officer directly owned 239,413 shares in the company, valued at $5,370,033.59. This trade represents a 62.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 13,774,601 shares of company stock valued at $289,306,296. Company insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ROIV. The Goldman Sachs Group upped their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Guggenheim restated a “buy” rating and issued a $28.00 price objective on shares of Roivant Sciences in a report on Thursday, December 18th. Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a report on Thursday, September 18th. Finally, Jefferies Financial Group boosted their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $25.19.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $21.93 on Friday. The company has a market capitalization of $15.25 billion, a price-to-earnings ratio of -39.16 and a beta of 1.22. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $23.47. The company’s 50-day moving average is $20.95 and its 200 day moving average is $15.86.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.